Following the vendor qualification in July, SANOFI rushed to place not just one but two orders with Medicollect.
In line with Medicollect’s core competence, the company will assist SANOFI with recruiting people with diabetes for 2 clinical trials in UK.
Rene Ludwigs, CEO in Medicollect, is particular proud of these projects: “SANOFI is the worlds second largest producer of diabetes medicines.
So to have them requesting our services is a true seal of approval to us. We are of course proud that global pharmaceutical companies find our patient recruitment services is the best solution in the market”.
Want to know more?
Since 2014, Medicollect has been working with the worlds largest pharmaceutical companies, helping them recruit patients for their clinical trials.
As projects scale up, the time has come to focus on vendor qualifications. Until recently, both Novartis and MSD have completed these extensive qualification procedures and approved the Medicollect set-up.
SANOFI is the latest, scrutinizing all SOP’s submitted by Medicollect for vendor qualification, making it the third finalized procedure from a global pharmaceutical company.
As Rene Ludwigs, CEO of Medicollect, phrases it, “We are, of course, proud that global pharmaceutical companies are eager to enter into vendor partnerships with Medicollect. We focus exclusively on solving the recruitment challenges faced by companies involved with clinical trials and our services put forth the best solution the market has to offer right now”.
Want to know more?
Medicollect is proud to present Enroller, a truly innovative IT project the company has been involved in since late 2015.
Enroller is a software solution developed specifically for presenting elevated security level patient data to hospital personnel in a user friendly way.
As a screening tool, Enroller captures all data gathered throughout the screening process, providing a total picture of the patient at a glance for Medicollect staff as well as hospital personnel. Enroller not only speeds up the process of screening patients for clinical trials, it also improves the quality of the screening and elevates the level of security with which patients’ sensitive information is treated.
The project is sponsored by the Innovation Fund Denmark, and has been developed in close partnership with the Danish diabetes community, The Life With Diabetes.
For introduction to Enroller, please contact CEO Rene Ludwigs.